Against steep odds and well-established paradigms, these four companies have successfully been commercializing their products ...

Under the Inflation Reduction Act, medications with the same active ingredient will be treated as the same drug for price ...

Though nerves abound for funders and founders in the industry, money continues to flow into startups, sometimes in ...

The FDA’s dramatic summer continues to unfold as news broke late Tuesday evening that Vinay Prasad will depart the agency, ...

In a surprise double announcement Tuesday, Novo reduced sales guidance by 5%—attributing the change to slowed growth of its ...

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

While some analysts forecasted the tariffs could mean billions in additional industry expenditure, others expect the overall ...

CEO Rob Davis referred to the cost reduction program as a “reallocation” rather than a cut, with the savings to be reinvested ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

Six weeks after HHS Secretary RFK Jr. cited unexplained conflicts of interest in dismissing all 17 members of the CDC’s vaccine advisory committee, Democrats are asking for details.

The Commissioner’s National Priority Vouchers aim to offer accelerated pathways to drugs that meet certain criteria, perhaps ...

The star of GSK’s Hengrui partnership is the COPD candidate HRS-9821, which will complement the pharma’s respiratory pipeline ...